ADX10059 Migraine Prevention Study

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of ADX10059 to prevent migraine attacks

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Addex Pharma S.A.

Criteria

Inclusion Criteria:

• Male and female patients aged 18 to 65 years

• History of migraine

• Aged ≤ 50 years at onset of migraine history

Exclusion Criteria:

• Cluster headache or chronic migraine headaches

• Currently uses, or within 3 months of Screening, has used: sodium valproate or topiramate and any other drugs used specifically for migraine prophylaxis, for example beta-blockers, calcium channel blockers, tricyclic antidepressants, selective serotonin reuptake inhibitors

• Unable to distinguish migraine headache from tension and other types of headache

• Current history of psychiatric disorder requiring regular medication

• Known history of alcohol abuse

• Known clinically significant allergy or known hypersensitivity to drugs

• History of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study

• Pregnant or breast-feeding